

**Yale Program For
Women's Reproductive
Behavioral Health
(WRBH)**

Medication Treatment Trial of Atomoxetine in Menopausal Women

The purpose of this study is to examine the efficacy of atomoxetine (ATX) treatment for the mild to moderate cognitive disturbances frequently experienced by women during the menopause transition (ages 40-60).

Atomoxetine, also known as Strattera®, is FDA-approved to treat adults with attention deficit disorder (ADHD). We are examining whether and to what degree peri- and early post-menopausal women experience cognitive disturbances that overlap with the impairments of executive function characteristic of ADHD. Participants are paid up to \$320 for their time and travel to the Program. (HIC #26533). For more information visit www.research4women.org or call 203-764-7520.